BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22934812)

  • 1. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
    Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
    Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import.
    Darovic S; Prpar Mihevc S; Župunski V; Gunčar G; Štalekar M; Lee YB; Shaw CE; Rogelj B
    J Cell Sci; 2015 Nov; 128(22):4151-9. PubMed ID: 26403203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS.
    Dormann D; Madl T; Valori CF; Bentmann E; Tahirovic S; Abou-Ajram C; Kremmer E; Ansorge O; Mackenzie IR; Neumann M; Haass C
    EMBO J; 2012 Nov; 31(22):4258-75. PubMed ID: 22968170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical FTLD-FUS associated with ALS-TDP: a case report.
    Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
    Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of heterogeneous nuclear ribonucleoproteins in frontotemporal lobar degeneration with FUS-positive inclusions.
    Gami-Patel P; Bandopadhyay R; Brelstaff J; Revesz T; Lashley T
    Neurobiol Aging; 2016 Oct; 46():192-203. PubMed ID: 27500866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import.
    Dormann D; Rodde R; Edbauer D; Bentmann E; Fischer I; Hruscha A; Than ME; Mackenzie IR; Capell A; Schmid B; Neumann M; Haass C
    EMBO J; 2010 Aug; 29(16):2841-57. PubMed ID: 20606625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneous nuclear ribonucleoproteins R and Q accumulate in pathological inclusions in FTLD-FUS.
    Gittings LM; Foti SC; Benson BC; Gami-Patel P; Isaacs AM; Lashley T
    Acta Neuropathol Commun; 2019 Feb; 7(1):18. PubMed ID: 30755280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
    J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TDP-43 and FUS: a nuclear affair.
    Dormann D; Haass C
    Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain.
    Aoki N; Higashi S; Kawakami I; Kobayashi Z; Hosokawa M; Katsuse O; Togo T; Hirayasu Y; Akiyama H
    Acta Neuropathol; 2012 Sep; 124(3):383-94. PubMed ID: 22526020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes.
    Davidson YS; Robinson AC; Hu Q; Mishra M; Baborie A; Jaros E; Perry RH; Cairns NJ; Richardson A; Gerhard A; Neary D; Snowden JS; Bigio EH; Mann DM
    Neuropathol Appl Neurobiol; 2013 Feb; 39(2):157-65. PubMed ID: 22497712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis.
    Deng HX; Zhai H; Bigio EH; Yan J; Fecto F; Ajroud K; Mishra M; Ajroud-Driss S; Heller S; Sufit R; Siddique N; Mugnaini E; Siddique T
    Ann Neurol; 2010 Jun; 67(6):739-48. PubMed ID: 20517935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and behavioural abnormalities in the FUS-tg mice mimic frontotemporal lobar degeneration: Effects of old and new anti-inflammatory therapies.
    de Munter J; Babaevskaya D; Wolters EC; Pavlov D; Lysikova E; V Kalueff A; Gorlova A; Oplatchikova M; Pomytkin IA; Proshin A; Umriukhin A; Lesch KP; Strekalova T
    J Cell Mol Med; 2020 Sep; 24(17):10251-10257. PubMed ID: 32667139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.